Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

By G. Valabrega, F. Montemurro, M. Aglietta. Annals of Oncology, 2007

639 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/86fd486bc6633621bd0fc3276a5f13eaec2fde59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Claudia Cava
2. Isabella Castiglioni
3. Gloria Bertoli

In Radiology, Nuclear Medicine and Imaging

1. Claudia Cava
2. Isabella Castiglioni
3. Gloria Bertoli

Citations in the corpus

• Protein therapeutics: a summary and pharmacological classification (2008, background): “It is therefore likely that a combination of mechanisms accounts for the therapeutic activity of trastuzumab, including inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, inhibition of angiogenesis and inhibition of HER2 receptor cleavag”
• MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, methodology): “miR-26a, miR-30b, let-7 family, miR-125a/b Prediction of therapy response (H) Tissue Microarray/ 83 BC + H vs adiacent stromal microdissected cells With SVM technique, they developed a 35 miRNA signature for H treatment response [216]”